

## INFORMATION DISCLOSURE STATEMENT

FORM PTO 1449 (modified)

ATTY DOCKET NO.  
2005\_0859ASERIAL NO.  
10/537,313U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEAPPLICANT  
Michiaki NAGASAWA et al.LIST OF REFERENCES CITED BY APPLICANT(S)  
(Use several sheets if necessary)FILING DATE  
June 2, 2005

GROUP

Date Submitted to PTO: August 31, 2005

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AE						
	AG						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
JK	AJ	2000-224992	08/2000	JP			
JK	AK	11-302190	11/1999	JP			
JK	AL	01/40226	06/2001	WO			
JK	AM	01/24781	04/2001	WO			
JK	AN	00/09127	02/2000	WO			

## OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

JK	AO	"Inhibitory Effect of Ibudilast (KC-404) on Cyclic Nucleotide Phosphodiesterases", Seiko Murashima: Mie Prefectural College of Nursing, et al., (Jpn Pharmacol Ther) Vol. 26, No. 1 (1998), 41-45.
JK	AP	"Possible role of cyclic AMP phosphodiesterases in the actions of ibudilast on eosinophil thromboxane generation and airways smooth muscle tone" John E. Souness et al., Br.J. Pharmacol. (1994) 111, 1081-1088.
JK	AQ	"Ibudilast Modulates Platelet-Endothelium Interaction Mainly Through Cyclic GMP-Dependent Mechanism", Journal of Cardiovascular Pharmacology 36(1) pp 65-70 (2000), KISHI, Y. et al.
JK	AR	"Drug for improvement of Brain Circulation and Metabolism, and How to Use It", Hirotoshi Kasahara, et al., Clinica, 1990, 17 (5), pages 256-262.

EXAMINER

DATE CONSIDERED

07-24-07